Mirae Asset Global Investments
ACRV icon

Mirae Asset Global Investments’s Acrivon Therapeutics ACRV Stock Holding History

Mirae Asset Global Investments’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,216
Closed -$2.2K – 1645
2025
Q3 		$2.2K Buy
1,216
+5
+0.4% +$7 ﹤0.01% 1634
2025
Q2 		$1.44K Buy
1,211
+169
+16% +$232 ﹤0.01% 1571
2025
Q1 		$2.33K Buy
1,042
+4
+0.4% +$22 ﹤0.01% 1535
2024
Q4 		$6.14K Buy
+1,038
New +$7.54K ﹤0.01% 1544

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Mirae Asset Global Investments's ACRV Position: Q4 2025 in Review

Mirae Asset Global Investments sold out of Acrivon Therapeutics (ACRV) in Q4 2025, closing a stake of 1,216 shares — an estimated $2.2K sold.

Mirae Asset Global Investments first reported a position in ACRV in Q4 2024 and held it in 4 quarters. The position peaked at $6.14K in Q4 2024. 48 funds tracked by Wall St. Rank hold ACRV as of Q4 2025.

  • Mirae Asset Global Investments reported no remaining Acrivon Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Mirae Asset Global Investments sold 1,216 Acrivon Therapeutics shares in Q4 2025, an estimated $2.2K.
  • Mirae Asset Global Investments first reported a position in Acrivon Therapeutics in Q4 2024 and held it in 4 quarters.
  • Mirae Asset Global Investments's Acrivon Therapeutics position peaked at $6.14K in Q4 2024.
  • 48 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q4 2025.

Based on Mirae Asset Global Investments's 13F filing for Q4 2025, filed 26 Jan 2026.